XTL Biopharmaceuticals Ltd.
XTLB
$1.35
-$0.085-5.94%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.65% | -16.68% | -10.83% | -17.48% | -15.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.07% | -16.05% | -10.98% | -15.84% | -14.65% |
| Operating Income | 13.07% | 16.05% | 10.98% | 15.84% | 14.65% |
| Income Before Tax | -32.20% | -250.23% | -287.51% | -522.71% | -409.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.20% | -250.23% | -287.51% | -522.71% | -409.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.20% | -250.23% | -287.51% | -522.71% | -409.17% |
| EBIT | 13.07% | 16.05% | 10.98% | 15.84% | 14.65% |
| EBITDA | 13.08% | 16.06% | 10.99% | 15.85% | 14.66% |
| EPS Basic | -32.00% | -255.56% | -296.30% | -610.00% | -516.67% |
| Normalized Basic EPS | -300.00% | -107.14% | -107.14% | -91.67% | -91.67% |
| EPS Diluted | -44.00% | -438.46% | -507.69% | -1,175.00% | -212.50% |
| Normalized Diluted EPS | -300.00% | -110.53% | -110.53% | -66.67% | -66.67% |
| Average Basic Shares Outstanding | 0.00% | 0.01% | 0.34% | 1.13% | 1.97% |
| Average Diluted Shares Outstanding | 0.00% | -13.29% | -13.04% | -12.44% | -11.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |